SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.530
+0.060 (1.73%)
At close: Apr 28, 2026, 4:00 PM EDT
3.500
-0.030 (-0.85%)
After-hours: Apr 28, 2026, 6:20 PM EDT
SAB Biotherapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for SAB Biotherapeutics stock have an average target of 10.75, with a low estimate of 7.00 and a high estimate of 15. The average target predicts an increase of 204.53% from the current stock price of 3.53.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 11, 2026.
Analyst Ratings
The average analyst rating for SAB Biotherapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 5 | 5 | 5 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $14 | Strong Buy | Maintains | $12 → $14 | +296.60% | Mar 11, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $7 | Strong Buy | Maintains | $9 → $7 | +98.30% | Mar 10, 2026 |
| UBS | UBS | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +98.30% | Jan 7, 2026 |
| Guggenheim | Guggenheim | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +324.93% | Dec 19, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +239.94% | Dec 18, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
127.50K
EPS This Year
-0.80
from -0.79
EPS Next Year
-0.48
from -0.80
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 525,000 | ||||||
| Avg | n/a | 127,500 | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.43 | -0.30 | |||
| Avg | -0.80 | -0.48 | |||
| Low | -1.31 | -0.82 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.